Development
AstraZeneca PLC
AZN
$73.01
$0.130.18%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 81.11% | 189.02% | 591.86% | 542.62% | 2,835.71% |
| Total Depreciation and Amortization | -6.32% | 34.15% | -3.63% | 15.12% | 28.20% |
| Total Amortization of Deferred Charges | -4.11% | 363.49% | 363.49% | 363.49% | 363.49% |
| Total Other Non-Cash Items | 61.54% | -239.08% | -2,880.88% | -336.07% | -895.22% |
| Change in Net Operating Assets | -92.01% | -86.86% | -82.59% | -16.06% | 85.90% |
| Cash from Operations | 5.48% | 17.39% | 33.64% | 33.71% | 64.48% |
| Capital Expenditure | -24.75% | -15.93% | -7.68% | -2.66% | 0.00% |
| Sale of Property, Plant, and Equipment | -53.19% | 1,880.00% | 4,433.33% | 4,422.22% | 2,069.23% |
| Cash Acquisitions | -6.18% | -0.29% | 89.16% | 87.98% | 89.77% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -55.56% | 11.65% | -97.72% | -306.58% | -914.60% |
| Cash from Investing | -37.30% | 10.71% | 69.56% | 65.72% | 73.23% |
| Total Debt Issued | 5,274.32% | 165.35% | -31.22% | -72.06% | -99.43% |
| Total Debt Repaid | -243.89% | -46.90% | 36.46% | 31.34% | 71.28% |
| Issuance of Common Stock | 13.79% | 0.00% | 3.57% | -3.45% | 0.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -2.68% | -2.64% | -2.39% | -1.88% | -13.17% |
| Other Financing Activities | 15.38% | 25.98% | 22.81% | 22.74% | -488.20% |
| Cash from Financing | 3.75% | 11.73% | 10.20% | -293.71% | -286.98% |
| Foreign Exchange rate Adjustments | 25.00% | 20.00% | -104.44% | -1,950.00% | -29.03% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -529.09% | 118.14% | 109.25% | 125.21% | 96.35% |